MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorYingbin Liu, MD, PhD, FACS
About this trial
Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.
Eligibility criteria
Qualifiers
Age range between 18 and 80 years old;
Identification of pancreatic space-occupying lesions through imaging examinations, with a high suspicion of pancreatic malignant tumors and planned for surgical treatment or tissue biopsy for pathological confirmation;
According to RECIST 1.1 evaluation criteria, having at least one measurable lesion (the longest diameter of the target lesion on spiral CT scan ≥10mm);
Ability to provide tumor tissue and blood samples;
Disqualifiers
Unable to provide tumor tissue and blood samples;
Previously received molecular targeted therapy, immunotherapy, or anti-tumor radiochemotherapy before this study;
History of malignancies other than pancreatic malignancy;
Presence of other severe diseases, including but not limited to uncontrolled congestive heart failure (NYHA class III or IV), unstable angina, poorly controlled arrhythmias, uncontrolled moderate to severe hypertension (SBP > 160mmHg or DBP > 100mmHg);
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,000 Participants
are grouped into 2 trial groupsSponsors and collaborators
Yingbin Liu, MD, PhD, FACS
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Sponsor institution
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Collaborator
Ruijin Hospital
Collaborator
Changhai Hospital
Collaborator
Source ClinicalTrials.gov